the present report describes for the first time the clinical efficacy of curcumin the active constituent of rhizomes of curcuma longa in the treatment of patients suffering from idiopathic inflammatory orbital pseudotumourscurcumin was administered orally at a dose of 375 mg3 timesday orally for a period of 622 months in eight patientsthey were followed up for a period of 2 years at 3 monthly intervalsfive patients completed the study out of which four recovered completely and in one patient the swelling regressed completely but some limitation of movement persistedno side effect was noted in any patient and there was no recurrenceit is suggested that curcumin could be used as a safe and effective drug in the treatment of idiopathic inflammatory orbital pseudotumourscopyright 2000 john wiley  sons ltd